Bioventus shares fell 16.8% after earnings, with the most evident pressure point being softness in bone graft substitutes, down 6%, despite 3% overall revenue growth. The transcript also points to continued investment in growth initiatives, while the outlook details needed to assess the guidance update are not included.
Bioventus shares rose 4.2% post-earnings, driven by better-than-expected revenue growth and encouraging momentum across key growth segments, particularly Pain Treatments. The reaffirmation of full-year guidance and positive strategic developments underpinned investor optimism.